Sonnet Bio

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination bit.ly/48qxQq8 $SONN

Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc bit.ly/3M5j1C5 $SONN

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting bit.ly/49pKB6D $SONN #Oncology #SolidTumors

#DidYouSee: We entered into a collaboration with Spanios to evaluate SON-1010 (IL-12-FHAB) using a patient-derived tumoroid platform to support an ongoing Phase 1 study in patients with sarcoma. Learn more: bit.ly/3Wc1hqq $SONN #Oncology #Sarcoma #SolidTumors

Gynecologic Cancer Awareness Month may be ending, but our commitment doesn’t stop. Find out how you can get involved and make a difference: bit.ly/3WVPayQ $SONN #GynecologicCancer #CancerAwareness

Our Fully Human Albumin-Binding (FHAB) construct is the foundation of a fully modular technology that enables the design of single or bifunctional biologic compounds that target solid tumors by binding albumin, which in turn, binds to FcRn, GP60 and SPARC. $SONN

Our CEO, Raghu Rao, provides an update on SON-1010, highlighting progress in finding the optimal dose with atezolizumab, monitoring patient safety and responses and preparing to test a higher dose as the study advances toward Part 2. $SONN #Oncology #SolidTumors

Sonnet to Present at the MedInvest Biotech & Pharma Conference bit.ly/4mprmwK $SONN #Oncology #SolidTumors

Stay informed on the latest news, clinical updates and company announcements from Sonnet. Sign up for email alerts here: bit.ly/4cOlI3c $SONN #Oncology #SolidTumors

We recently participated in a #VirtualInvestor #WhatThisMeans segment, where CMO Dr. Richard Kenney discussed the expansion of the SB221 trial in platinum-resistant #OvarianCancer and our plans to evaluate higher doses ahead of Phase 2a next year. vimeo.com/1108857330?share=c… $SONN

💜 September is #OvarianCancerAwarenessMonth — a time to unite, raise awareness and support those affected. Learn how you can make an impact: bit.ly/3YALP7u $SONN #Oncology #OvarianCancer #EndOvarianCancer

This September, we’re shining a light on Gynecologic Cancer Awareness Month. Join us in supporting patients, spreading awareness and making a difference: bit.ly/3WVPayQ $SONN #GynecologicCancer #CancerAwareness

The Sonnet team combines unparalleled expertise in cytokine biology with extensive, proven success in drug discovery and development — driving innovation that transforms patient care. Explore more about $SONN leadership here: bit.ly/3WAGFsM #Oncology #SolidTumors

Tumors often resist immunotherapy by creating an immune-suppressive tumor microenvironment. We're working to address this, with our technology designed to deliver immune-activating cytokines like IL-12 directly to the TME — enhancing half-life, safety, and therapeutic benefit.

Stay informed — sign up for email alerts and never miss an update: bit.ly/4cOlI3c $SONN #Oncology #SolidTumors

Sonnet Releases Virtual Investor "What This Means" Segment bit.ly/3H8RLjX $SONN #Oncology #SolidTumors

#InCaseYouMissedIt: We recently announced an $888 million business combination to launch Sonnet BioTherapeutics’ HYPE Cryptocurrency Treasury Reserve Strategy. Learn more about this here: bit.ly/4nHnlpb $SONN #Oncology #SolidTumors

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer bit.ly/45iQcro $SONN #Oncology #SolidTumors

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy bit.ly/4nHnlpb $SONN